Transforming growth factor β family signaling pathways in ovarian and uterine biology

卵巢和子宫生物学中转化生长因子β家族信号通路

基本信息

  • 批准号:
    10396521
  • 负责人:
  • 金额:
    $ 47.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1994
  • 资助国家:
    美国
  • 起止时间:
    1994-08-17 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The transforming growth factor β (TGFβ) superfamily is the largest family of secreted proteins in mammals. These dimeric ligands, which function in nearly every developmental, physiologic, and pathophysiologic process, including infertility, signal through a heterodimeric complex of type 2 and type 1 serine-threonine kinase receptors that phosphorylate downstream regulatory SMAD proteins and bind SMAD4 to regulate transcription. With NICHD support that started with a physician scientists award (K11HD00960; 1991-93) and this R01 grant (1994-present), we have been productive leaders in the identification and characterization of the oocyte-secreted TGFβ family members, growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15), and granulosa cell-secreted activins and inhibins. We have published extensively in this field including >30 papers in Nature, Nature Genetics, Nature Medicine, PLoS Biology, PLoS Genetics, PNAS, and Science. Whereas mammalian oocytes were initially hypothesized to be passengers rather than drivers in ovarian folliculogenesis, we showed that GDF9 is essential for fertility, discovered the X-linked BMP15 gene, and showed that GDF9:BMP heterodimers are the most active oocyte-secreted ligand in mice and women. These insights have defined the oocyte-somatic cell dialogue in ovarian folliculogenesis. In parallel, we showed that inhibin α-knockout mice are infertile, develop ovarian cancers and die due to an activin-induced cachexia syndrome. BMPs, GDF9:BMP15, activins, and myostatin share common type 2 receptors [activin receptor type 2A (ACVR2A) or type 2B (ACVR2B) or BMPR2], type 1 receptors (ALK4 and ALK5), and receptor-regulated SMADs (SMAD1,2,3,5). Using mouse genetics, we have shown that these proteins function in the pituitary, ovaries, and uterus (e.g., granulosa-specific knockout of SMAD2 and SMAD3 leads to cumulus defects and infertility due to defective GDF9:BMP15 signaling, whereas uterine-specific knockout of SMAD2 and SMAD3 leads to infertility secondary to endometrial hyperplasia). Although SMAD2 and SMAD3 play redundant roles in GDF9:BMP15, activin, and TGFβ signaling, we know little about the transcriptional complexes or DNA sequences that they bind. In addition, there are no small molecule inhibitors of ACVR2A/2B and BMPR2. Our overall hypothesis is that oocyte GDF9:BMP15, granulosa cell activins, and uterine BMPs and TGFβs signal through unique SMAD-mediated transcriptional complexes to regulate ovarian and uterine physiology in mice and women. Our proposal will take advantage of state-of-the-art CRISPR/Cas9 strategies to manipulate the mouse genome and DNA-encoded chemical libraries to create novel inhibitors of ACVR2A/2B and BMPR2 and perform follow-up genetic, proteomic, and biochemical approaches to reach our goals. At the end of 5 years, we expect to have unlocked key molecular events that are orchestrated by TGFβ family ligands in the female reproductive tract, thereby accelerating translational research to optimize assisted reproductive procedures for women and to create the first ACVR2A/2B and BMPR2 specific small molecules to regulate female fertility.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARTIN M. MATZUK其他文献

MARTIN M. MATZUK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARTIN M. MATZUK', 18)}}的其他基金

Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10682061
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
  • 批准号:
    10674987
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10764639
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10419647
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
使用特定 KLK3 抑制剂作为新避孕药破坏精液液化
  • 批准号:
    10598585
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Kinases as Therapeutic Targets for Endometriosis
激酶作为子宫内膜异位症的治疗靶点
  • 批准号:
    10532966
  • 财政年份:
    2022
  • 资助金额:
    $ 47.56万
  • 项目类别:
Targeting testis-specific ubiquitin-proteasome pathways for male contraception
针对男性避孕的睾丸特异性泛素蛋白酶体途径
  • 批准号:
    10018522
  • 财政年份:
    2019
  • 资助金额:
    $ 47.56万
  • 项目类别:
Functional genomics and DEC-Tec to identify germ cell-specific contraceptives
功能基因组学和 DEC-Tec 鉴定生殖细胞特异性避孕药
  • 批准号:
    10164823
  • 财政年份:
    2017
  • 资助金额:
    $ 47.56万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    9278437
  • 财政年份:
    2017
  • 资助金额:
    $ 47.56万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10164824
  • 财政年份:
    2017
  • 资助金额:
    $ 47.56万
  • 项目类别:

相似海外基金

Effects of activins and activin-binding proteins on fetal lung development
激活素和激活素结合蛋白对胎儿肺发育的影响
  • 批准号:
    23K08875
  • 财政年份:
    2023
  • 资助金额:
    $ 47.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Targeting Activins to treat cachexia
靶向激活素治疗恶病质
  • 批准号:
    nhmrc : 1078907
  • 财政年份:
    2015
  • 资助金额:
    $ 47.56万
  • 项目类别:
    Project Grants
Targeting Activins to treat cachexia
靶向激活素治疗恶病质
  • 批准号:
    nhmrc : GNT1078907
  • 财政年份:
    2015
  • 资助金额:
    $ 47.56万
  • 项目类别:
    Project Grants
INTERACTIONS OF ACTIVINS AND BMP WITH THEIR RECEPTORS
激活素和 BMP 与其受体的相互作用
  • 批准号:
    7537247
  • 财政年份:
    2007
  • 资助金额:
    $ 47.56万
  • 项目类别:
INTERACTIONS OF ACTIVINS AND BMP WITH THEIR RECEPTORS
激活素和 BMP 与其受体的相互作用
  • 批准号:
    6849106
  • 财政年份:
    2003
  • 资助金额:
    $ 47.56万
  • 项目类别:
ROLE OF ACTIVINS IN BRANCHING MORPHOGENESIS OF THE PROSTATE AND OTHER ORGANS
激活素在前列腺和其他器官分支形态发生中的作用
  • 批准号:
    nhmrc : 7191
  • 财政年份:
    2001
  • 资助金额:
    $ 47.56万
  • 项目类别:
    Early Career Fellowships
Biology of activins in fetoplacental hypoxia
胎儿胎盘缺氧中激活素的生物学
  • 批准号:
    nhmrc : 143769
  • 财政年份:
    2001
  • 资助金额:
    $ 47.56万
  • 项目类别:
    NHMRC Postgraduate Scholarships
Roles of inhibins, activins, and follistation in reproductive systems.
抑制素、激活素和卵泡在生殖系统中的作用。
  • 批准号:
    10460135
  • 财政年份:
    1998
  • 资助金额:
    $ 47.56万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B).
FUNCTIONAL ANALYSIS OF ACTIVINS DURING DEVELOPMENT
发育过程中激活素的功能分析
  • 批准号:
    6125677
  • 财政年份:
    1994
  • 资助金额:
    $ 47.56万
  • 项目类别:
FUNCTIONAL ANALYSIS OF ACTIVINS DURING DEVELOPMENT
发育过程中激活素的功能分析
  • 批准号:
    6476789
  • 财政年份:
    1994
  • 资助金额:
    $ 47.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了